2024年欧洲肿瘤内科学会妇科肿瘤学大会(ESMO GC)将于2024年6月20日至22日在意大利佛罗伦萨以线上线下结合形式举行。 本次会议内容主要涵盖妇科肿瘤诊治临床实践进展、PARP抑制剂治疗卵巢癌的新进展、宫颈癌和子宫内膜癌诊断和管理的新技术、手术和腹腔热灌...
Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherw...
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2024 Abstract Book, a supplement to the official ESMO journal,ESMO Open. Publication schedule of accepted abstracts Abstracts accepted for presentation during the ESMO Breast Cancer 2024 will be released...
Abstract submission categories-摘要提交类别 *Abstracts may also be submitted to the Cancer nursing track. Submissions in these categories will be reviewed by the European Oncology Nursing Society (EONS) Scientific Committee for selection and presentation in the EONS cancer nursing programme. Unless otherw...
点此提交摘要>>>Submit Abstract>>> ESMO TAT 2024 Abstract Regulations>>>提交指南 Abstract submission categories Antibody-based therapies Cellular and gene therapies DNA damage repair and epigenetics Immunotherapy Kinase-targeting agents and cell signalling modulators ...
Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2024, which is taking place virtually and in-person in B
2025. Detailed final results from CABINET were presented at ESMO 2024 and were concurrently published in the New England Journal of Medicine, which supported the addition of cabo to the recently updated NCCN guidelines for NET. We're collaborating closely with the FDA on the review and won't ...
2024. https://www.urotoday.com/conference-highlights/esmo-2024/esmo-2024-prostate-cancer/154816-esmo-2024-invited-discussant-eortc-gucg-1333-peace-3.html. Accessed 02 Dec 2024 Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, et al. Addition of radium-223 to abiraterone acetate ...
The new drug application for fulzerasib monotherapy in treating advanced KRAS G12C-mutant NSCLC has been accepted and granted priority review designation by China's National Medical Products Administration (NMPA). Based on the data presented at 2023 ESMO Asia, the registrational phase II study of...
Abstract submission deadlines 点此提交摘要>>>Submit Abstract>>> 提交指南>>>ESMO Sarcoma and Rare Cancers 2024 Abstract Regulations Submission categories Central Nervous System (CNS) Digestive cancers Genitourinary cancers Gynaecological cancers Head and neck cancers ...